106 related articles for article (PubMed ID: 37667956)
21. A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab.
Kuba K; Inoue H; Matsumura S; Enoki Y; Kogashiwa Y; Ebihara Y; Nakahira M; Yamazaki T; Yasuda M; Kaira K; Kagamu H; Sugasawa M
Sci Rep; 2022 Dec; 12(1):22557. PubMed ID: 36581686
[TBL] [Abstract][Full Text] [Related]
22. Control of autoimmune myocarditis and multiorgan inflammation by glucocorticoid-induced TNF receptor family-related protein(high), Foxp3-expressing CD25+ and CD25- regulatory T cells.
Ono M; Shimizu J; Miyachi Y; Sakaguchi S
J Immunol; 2006 Apr; 176(8):4748-56. PubMed ID: 16585568
[TBL] [Abstract][Full Text] [Related]
23. Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
Ikeda T; Ishihara H; Nemoto Y; Tachibana H; Fukuda H; Yoshida K; Takagi T; Iizuka J; Hashimoto Y; Ishida H; Kondo T; Tanabe K
Urol Oncol; 2021 Oct; 39(10):735.e9-735.e16. PubMed ID: 34172370
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study.
Ishihara H; Nemoto Y; Nakamura K; Ikeda T; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Takagi T; Ishida H; Kondo T; Tanabe K
Target Oncol; 2021 Jul; 16(4):493-502. PubMed ID: 34173936
[TBL] [Abstract][Full Text] [Related]
25. Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma.
Polimeno M; Napolitano M; Costantini S; Portella L; Esposito A; Capone F; Guerriero E; Trotta A; Zanotta S; Pucci L; Longo N; Perdonà S; Pignata S; Castello G; Scala S
BJU Int; 2013 Sep; 112(5):686-96. PubMed ID: 23495770
[TBL] [Abstract][Full Text] [Related]
26. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
Cohen AD; Schaer DA; Liu C; Li Y; Hirschhorn-Cymmerman D; Kim SC; Diab A; Rizzuto G; Duan F; Perales MA; Merghoub T; Houghton AN; Wolchok JD
PLoS One; 2010 May; 5(5):e10436. PubMed ID: 20454651
[TBL] [Abstract][Full Text] [Related]
27. Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma.
Ficial M; Jegede OA; Sant'Angelo M; Hou Y; Flaifel A; Pignon JC; Braun DA; Wind-Rotolo M; Sticco-Ivins MA; Catalano PJ; Freeman GJ; Sharpe AH; Hodi FS; Motzer RJ; Wu CJ; Atkins MB; McDermott DF; Shukla SA; Choueiri TK; Signoretti S
Clin Cancer Res; 2021 Mar; 27(5):1371-1380. PubMed ID: 33219016
[TBL] [Abstract][Full Text] [Related]
28. Comparison of circulating and intratumoral regulatory T cells in patients with renal cell carcinoma.
Asma G; Amal G; Raja M; Amine D; Mohammed C; Amel BA
Tumour Biol; 2015 May; 36(5):3727-34. PubMed ID: 25563193
[TBL] [Abstract][Full Text] [Related]
29. Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program.
Rebuzzi SE; Signori A; Buti S; Banna GL; Murianni V; Damassi A; Maruzzo M; Giannarelli D; Tortora G; Galli L; Rizzo M; De Giorgi U; Antonuzzo L; Bracarda S; Cartenì G; Atzori F; Tamberi S; Procopio G; Fratino L; Lo Re G; Santoni M; Baldessari C; Astone A; Calabrò F; Brunelli M; Porta C; Rescigno P; Basso U; Fornarini G
ESMO Open; 2022 Dec; 7(6):100634. PubMed ID: 36493602
[TBL] [Abstract][Full Text] [Related]
30. Characterization of a new regulatory CD4+ T cell subset in primary Sjögren's syndrome.
Alunno A; Petrillo MG; Nocentini G; Bistoni O; Bartoloni E; Caterbi S; Bianchini R; Baldini C; Nicoletti I; Riccardi C; Gerli R
Rheumatology (Oxford); 2013 Aug; 52(8):1387-96. PubMed ID: 23674818
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study.
Velev M; Dalban C; Chevreau C; Gravis G; Negrier S; Laguerre B; Gross-Goupil M; Ladoire S; Borchiellini D; Geoffrois L; Joly F; Priou F; Barthelemy P; Laramas M; Narciso B; Thiery-Vuillemin A; Berdah JF; Ferrari V; Dominique Thomas Q; Mione C; Curcio H; Oudard S; Tantot F; Escudier B; Chabaud S; Albiges L; Thibault C
Eur J Cancer; 2023 Mar; 182():66-76. PubMed ID: 36746010
[TBL] [Abstract][Full Text] [Related]
32. C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma.
Noguchi G; Nakaigawa N; Umemoto S; Kobayashi K; Shibata Y; Tsutsumi S; Yasui M; Ohtake S; Suzuki T; Osaka K; Muraoka K; Hasumi H; Kondo K; Igarashi Y; Sasada T; Kishida T; Yao M
Cancer Chemother Pharmacol; 2020 Jul; 86(1):75-85. PubMed ID: 32537714
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
Ueda K; Suekane S; Kurose H; Chikui K; Nakiri M; Nishihara K; Matsuo M; Kawahara A; Yano H; Igawa T
Urol Oncol; 2018 Nov; 36(11):499.e9-499.e16. PubMed ID: 30131293
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial.
Basso U; Facchinetti A; Rossi E; Maruzzo M; Conteduca V; Aieta M; Massari F; Fraccon AP; Mucciarini C; Sava T; Santoni M; Pegoraro C; Durante E; Nicodemo M; Perin A; Bearz A; Gatti C; Fiduccia P; Diminutto A; Barile C; De Giorgi U; Zamarchi R; Zagonel V
Oncologist; 2021 Sep; 26(9):740-750. PubMed ID: 34077597
[TBL] [Abstract][Full Text] [Related]
35. Inflammatory Prognostic Index in Metastatic Renal Carcinoma Treated with Nivolumab.
Ekinci F; Erdogan AP; Yildirim S; Bulut G; Yilmaz C; Barutca S
J Coll Physicians Surg Pak; 2022 Oct; 32(10):1288-1294. PubMed ID: 36205273
[TBL] [Abstract][Full Text] [Related]
36. Prognostic impact of tumor-infiltrating CD276/Foxp3-positive lymphocytes and associated circulating cytokines in patients undergoing radical nephrectomy for localized renal cell carcinoma.
Iida K; Miyake M; Onishi K; Hori S; Morizawa Y; Gotoh D; Itami Y; Onishi S; Nakai Y; Anai S; Tanaka N; Fujimoto K
Oncol Lett; 2019 Apr; 17(4):4004-4010. PubMed ID: 30930997
[TBL] [Abstract][Full Text] [Related]
37. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment.
Strauss L; Bergmann C; Szczepanski M; Gooding W; Johnson JT; Whiteside TL
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4345-54. PubMed ID: 17671115
[TBL] [Abstract][Full Text] [Related]
38. Mast cell density in metastatic renal cell carcinoma: Association with prognosis and tumour-infiltrating lymphocytes.
Yao J; Xi W; Chen X; Xiong Y; Zhu Y; Wang H; Hu X; Guo J
Scand J Immunol; 2021 Apr; 93(4):e13006. PubMed ID: 33275792
[TBL] [Abstract][Full Text] [Related]
39. [Prognostic value of tumor infiltration immune cells in pancreatic cancer].
Zhao KL; Liu J; Jiang WN; Hao JH
Zhonghua Wai Ke Za Zhi; 2018 Jun; 56(6):464-470. PubMed ID: 29886672
[No Abstract] [Full Text] [Related]
40. The presence of tumour-infiltrating lymphocytes (TILs) and the ratios between different subsets serve as prognostic factors in advanced hypopharyngeal squamous cell carcinoma.
Wang J; Tian S; Sun J; Zhang J; Lin L; Hu C
BMC Cancer; 2020 Aug; 20(1):731. PubMed ID: 32758195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
